1. Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile. (October 2022) Authors: Pagliarini, R.; Milgram, B.C.; Borrelli, D.R.; Brooijmans, N.; Huff, M.R.; Ito, T.; Jonsson, P.; Ladd, B.; O'Hearn, E.; Wang, W.; Kuzmic, P.; Bellier, J.; Hata, A.N.; Guzman-Perez, A.; Stuart, D.D. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗